Alx Oncology Holdings (ALXO) Liabilities and Shareholders Equity (2019 - 2026)

Alx Oncology Holdings has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $178.3 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $178.3 million, up 47.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $415.4 million (down 37.91% YoY), and the FY2025 annual result was $59.0 million, down 60.04% from the prior year.
• Liabilities and Shareholders Equity came in at $178.3 million for Q1 2026 at Alx Oncology Holdings, up from $59.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $363.7 million in Q1 2022 to a low of $59.0 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $214.6 million (2024), against an average of $212.8 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 60.04% in 2025 and surged 47.5% in 2026, its largest moves.
• Alx Oncology Holdings' Liabilities and Shareholders Equity stood at $306.5 million in 2022, then retreated by 20.86% to $242.6 million in 2023, then plunged by 39.08% to $147.8 million in 2024, then sank by 60.04% to $59.0 million in 2025, then surged by 202.02% to $178.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $178.3 million (Q1 2026), $59.0 million (Q4 2025), and $82.7 million (Q3 2025), per Business Quant data.